

M Jahangir Alam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3422765/publications.pdf>

Version: 2024-02-01

74
papers

1,487
citations

361413

20
h-index

345221

36
g-index

75
all docs

75
docs citations

75
times ranked

1762
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with <i>Clostridioides difficile</i> Infection: A Phase 2a Multicenter Clinical Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1164-1170.	5.8	17
2	Multi-country surveillance of <i>Clostridioides difficile</i> demonstrates high prevalence of spores in non-healthcare environmental settings. <i>Anaerobe</i> , 2022, 75, 102543.	2.1	3
3	Draft genome sequence data of a clinical <i>Enterococcus faecalis</i> isolate SHH039 from a patient with cholecystitis from a tertiary care hospital in Sabah, Malaysia. <i>Data in Brief</i> , 2022, 41, 108019.	1.0	1
4	Isolation and characterisation of carbapenem-resistant <i>Pseudomonas aeruginosa</i> from hospital environments in tertiary care hospitals in Dhaka, Bangladesh. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 30, 31-37.	2.2	6
5	Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in <i>Clostridioides difficile</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	5
6	Visualization of fidaxomicin association with the exosporium layer of <i>Clostridioides difficile</i> spores. <i>Anaerobe</i> , 2021, 69, 102352.	2.1	7
7	Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab365.	0.9	18
8	Systems biology evaluation of refractory <i>Clostridioides difficile</i> infection including multiple failures of fecal microbiota transplantation. <i>Anaerobe</i> , 2021, 70, 102387.	2.1	8
9	Comparative clinical outcomes evaluation of hospitalized patients infected with <i>Clostridioides difficile</i> ribotype 106 vs. other toxigenic strains. <i>Anaerobe</i> , 2021, 72, 102440.	2.1	4
10	1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of <i>Clostridioides difficile</i> . <i>Open Forum Infectious Diseases</i> , 2021, 8, S617-S617.	0.9	1
11	701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, S451-S451.	0.9	0
12	Molecular epidemiology of toxigenic <i>Clostridioides difficile</i> isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. <i>Anaerobe</i> , 2020, 61, 102081.	2.1	3
13	Whole genome sequencing data of a clinical <i>Enterococcus gallinarum</i> strain EGR748 from Sabah, Malaysia. <i>Data in Brief</i> , 2020, 33, 106370.	1.0	2
14	In vitro activity of eravacycline against common ribotypes of <i>Clostridioides difficile</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2879-2884.	3.0	7
15	A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3635-3643.	3.0	12
16	<i>In Vitro</i> Activity of Omadacycline, a New Tetracycline Analog, and Comparators against <i>Clostridioides difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
17	Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz552.	0.9	13
18	PCR ribotypes of <i>Clostridioides difficile</i> across Texas from 2011 to 2018 including emergence of ribotype 255. <i>Emerging Microbes and Infections</i> , 2020, 9, 341-347.	6.5	21

#	ARTICLE	IF	CITATIONS
19	Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection. Open Forum Infectious Diseases, 2020, 7, ofaa476.	0.9	8
20	1197. Inhibitory Effect of Ursodeoxycholic Acid on <i>Clostridioides difficile</i> Growth. Open Forum Infectious Diseases, 2020, 7, S621-S621.	0.9	0
21	784. A Novel Method to Assess Virulence of <i>Clostridioides difficile</i> : Focus on <i>C. difficile</i> Ribotype 106. Open Forum Infectious Diseases, 2020, 7, S436-S437.	0.9	0
22	Molecular epidemiology of Clostridioides difficile in domestic dogs and zoo animals. Anaerobe, 2019, 59, 107-111.	2.1	5
23	Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil. Anaerobe, 2019, 58, 22-29.	2.1	12
24	Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains. Open Forum Infectious Diseases, 2019, 6, ofz013.	0.9	14
25	Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe, 2019, 56, 88-90.	2.1	6
26	LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase III C (polIII C) Inhibitor. Open Forum Infectious Diseases, 2019, 6, S995-S996.	0.9	3
27	1720. Isolation and Characterization of Candida auris From an Active Surveillance System in Texas. Open Forum Infectious Diseases, 2019, 6, S630-S630.	0.9	1
28	2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection. Open Forum Infectious Diseases, 2019, 6, S825-S825.	0.9	0
29	2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes. Open Forum Infectious Diseases, 2019, 6, S828-S828.	0.9	0
30	2410. Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital. Open Forum Infectious Diseases, 2019, 6, S832-S832.	0.9	0
31	2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations. Open Forum Infectious Diseases, 2019, 6, S896-S896.	0.9	1
32	2581. An Invertebrate Model to Study Gut Microbiome Dysbiosis. Open Forum Infectious Diseases, 2019, 6, S896-S897.	0.9	0
33	688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile. Open Forum Infectious Diseases, 2019, 6, S312-S313.	0.9	2
34	Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	13
35	Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clinical Infectious Diseases, 2019, 68, 1887-1893.	5.8	18
36	Accelerate PhenoTest TM BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. Annals of Pharmacotherapy, 2018, 52, 754-762.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Evaluation of a shoe sole UVC device to reduce pathogen colonization on floors, surfaces and patients. <i>Journal of Hospital Infection</i> , 2018, 98, 96-101.	2.9	20
38	471. Prevalence and Characteristics of <i>Clostridioides difficile</i> Infection in Bangladesh. <i>Open Forum Infectious Diseases</i> , 2018, 5, S176-S176.	0.9	0
39	710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in <i>Clostridioides difficile</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, S255-S256.	0.9	1
40	510. First Environmental Investigation of Toxigenic <i>Clostridium difficile</i> Strains in Texas Hospitals. <i>Open Forum Infectious Diseases</i> , 2018, 5, S189-S189.	0.9	0
41	Environmental transmission of <i>Clostridioides difficile</i> ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 1322-1329.	1.8	14
42	Cadazolid for the treatment of <i>Clostridium difficile</i> . <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 509-514.	4.1	24
43	A Protocol to Characterize the Morphological Changes of <i>Clostridium difficile</i> in Response to Antibiotic Treatment. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	2
44	Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of <i>Clostridium difficile</i> . <i>Archives of Microbiology</i> , 2017, 199, 317-323.	2.2	0
45	Community Environmental Contamination of Toxigenic <i>Clostridium difficile</i> . <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx018.	0.9	44
46	Antimicrobial Susceptibility Assessment of Clinical <i>Clostridium difficile</i> Isolates in Relation to CRISPR-Cas. <i>Open Forum Infectious Diseases</i> , 2017, 4, S132-S132.	0.9	0
47	First Environmental Investigation of Toxigenic <i>Clostridium difficile</i> at a Large Hospital in Bangladesh. <i>Open Forum Infectious Diseases</i> , 2017, 4, S406-S406.	0.9	0
48	Acquisition of <i>Clostridium difficile</i> Colonization and Infection After Transfer From a Veterans Affairs Hospital to an Affiliated Long-Term Care Facility. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 1070-1076.	1.8	21
49	Novel antibiotics in development to treat <i>Clostridium difficile</i> infection. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 1-7.	2.3	24
50	Evaluating the Effects of Surotomycin Treatment on <i>Clostridium difficile</i> Toxin A and B Production, Immune Response, and Morphological Changes. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3519-3523.	3.2	12
51	A novel method for imaging the pharmacological effects of antibiotic treatment on <i>Clostridium difficile</i> . <i>Anaerobe</i> , 2016, 40, 10-14.	2.1	7
52	A pilot study to assess bacterial and toxin reduction in patients with <i>Clostridium difficile</i> infection given fidaxomicin or vancomycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 22.	3.8	13
53	Impact on toxin production and cell morphology in <i>Clostridium difficile</i> by ridinilazole (SMT19969), a novel treatment for <i>C. difficile</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1245-1251.	3.0	54
54	In the Endemic Setting, <i>Clostridium difficile</i> Ribotype 027 Is Virulent But Not Hypervirulent. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1318-1323.	1.8	38

#	ARTICLE	IF	CITATIONS
55	Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of <i>Clostridium difficile</i> From Stool Samples. <i>Annals of Laboratory Medicine</i> , 2015, 35, 306-313.	2.5	23
56	Evaluation of Portability and Cost of a Fluorescent PCR Ribotyping Protocol for <i>Clostridium difficile</i> Epidemiology. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1192-1197.	3.9	46
57	Host Factors and Clinical Outcomes of <i>Candida</i> Colonization in Critically Ill Patients. <i>Mycopathologia</i> , 2015, 179, 87-93.	3.1	5
58	FKS Mutant <i>Candida glabrata</i> : Risk Factors and Outcomes in Patients With Candidemia. <i>Clinical Infectious Diseases</i> , 2014, 59, 819-825.	5.8	147
59	Investigation of potentially pathogenic <i>Clostridium difficile</i> contamination in household environs. <i>Anaerobe</i> , 2014, 27, 31-33.	2.1	50
60	Rapid Detection of Genetically Modified Ingredients in Soybean Products by Real-Time Loop-Mediated Isothermal Amplification. <i>Journal of Food and Nutrition Research (Newark, Del)</i> , 2014, 2, 363-368.	0.3	20
61	Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of <i>Candida</i> species using seeded blood samples. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 324-326.	1.8	71
62	Treatment of <i>Candida famata</i> bloodstream infections: case series and review of the literature. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 438-443.	3.0	49
63	Antibiotic Resistance and Growth of the Emergent Pathogen <i>Escherichia albertii</i> on Raw Ground Beef Stored under Refrigeration, Abuse, and Physiological Temperature. <i>Journal of Food Protection</i> , 2013, 76, 124-128.	1.7	17
64	Inhibition of Biofilm Formation by Esomeprazole in <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4360-4364.	3.2	22
65	Development of a fimY-based loop-mediated isothermal amplification assay for detection of <i>Salmonella</i> in food. <i>Food Research International</i> , 2012, 45, 1011-1015.	6.2	37
66	The respiratory burst activity and expression of catalase in white shrimp, <i>Litopenaeus vannamei</i> , during long-term exposure to pH stress. <i>Ecotoxicology</i> , 2012, 21, 1609-1616.	2.4	30
67	Rapid detection of food-borne <i>Listeria monocytogenes</i> by real-time quantitative loop-mediated isothermal amplification. <i>Food Science and Biotechnology</i> , 2012, 21, 101-106.	2.6	40
68	Prevalence and Persistence of <i>Salmonella</i> in Cohorts of Feedlot Cattle. <i>Foodborne Pathogens and Disease</i> , 2011, 8, 781-789.	1.8	15
69	Application of in situ loop-mediated isothermal amplification method for detection of <i>Salmonella</i> in foods. <i>Food Control</i> , 2011, 22, 438-444.	5.5	43
70	Genetic Variations in Shiga Toxin-Producing Abilities of Bovine and Human <i>Escherichia coli</i> O157:H7. <i>Zoonoses and Public Health</i> , 2011, 58, 185-191.	2.2	6
71	Resistance class 1 integron in clinical methicillin-resistant <i>Staphylococcus aureus</i> strains in southern China, 2001-2006. <i>Clinical Microbiology and Infection</i> , 2011, 17, 714-718.	6.0	127
72	Prevalence and antimicrobial resistance of <i>Salmonella</i> in retail foods in northern China. <i>International Journal of Food Microbiology</i> , 2010, 143, 230-234.	4.7	87

#	ARTICLE	IF	CITATIONS
73	First report of class 2 integron in clinical <i>Enterococcus faecalis</i> and class 1 integron in <i>Enterococcus faecium</i> in South China. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 315-317.	1.8	95
74	Studies on pathogenic <i>Vibrio parahaemolyticus</i> during a warm weather season in the Seto Inland Sea, Japan. <i>Environmental Microbiology</i> , 2003, 5, 706-710.	3.8	46